XML 31 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues
 12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Revenues
Revenues
Revenues by product and by geographic area
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold principally in Europe.
Revenues were as follows (in millions):
 
 
Year ended December 31, 2018
 
 
US
 
ROW
 
Total
Enbrel® (etanercept)
 
$
4,807

 
$
207

 
$
5,014

Neulasta® (pegfilgrastim)
 
3,866

 
609

 
4,475

Prolia® (denosumab)
 
1,500

 
791

 
2,291

Aranesp® (darbepoetin alfa)
 
942

 
935

 
1,877

XGEVA® (denosumab)
 
1,338

 
448

 
1,786

Sensipar® / Mimpara® (cinacalcet)
 
1,436

 
338

 
1,774

EPOGEN® (epoetin alfa)
 
1,010

 
—

 
1,010

Other products
 
2,530

 
1,776

 
4,306

Total product sales(1)
 
17,429

 
5,104

 
22,533

Other revenues
 
929

 
285

 
1,214

Total revenues(2)
 
$
18,358

 
$
5,389

 
$
23,747


 
 
Year ended December 31, 2017
 
 
US
 
ROW
 
Total
ENBREL
 
$
5,206

 
$
227

 
$
5,433

Neulasta®
 
3,931

 
603

 
4,534

Aranesp®
 
1,114

 
939

 
2,053

Prolia®
 
1,272

 
696

 
1,968

Sensipar® / Mimpara® 
 
1,374

 
344

 
1,718

XGEVA®
 
1,157

 
418

 
1,575

EPOGEN®
 
1,096

 
—

 
1,096

Other products
 
1,981

 
1,437

 
3,418

Total product sales(1)
 
17,131

 
4,664

 
21,795

Other revenues
 
898

 
156

 
1,054

Total revenues(2)
 
$
18,029

 
$
4,820

 
$
22,849

 
 
Year ended December 31, 2016
 
 
US
 
ROW
 
Total
ENBREL
 
$
5,719

 
$
246

 
$
5,965

Neulasta®
 
3,925

 
723

 
4,648

Aranesp®
 
1,082

 
1,011

 
2,093

Prolia®
 
1,049

 
586

 
1,635

Sensipar® / Mimpara® 
 
1,240

 
342

 
1,582

XGEVA®
 
1,115

 
414

 
1,529

EPOGEN®
 
1,282

 
—

 
1,282

Other products
 
1,913

 
1,245

 
3,158

Total product sales(1)
 
17,325

 
4,567

 
21,892

Other revenues
 
1,001

 
98

 
1,099

Total revenues(2)
 
$
18,326

 
$
4,665

 
$
22,991

____________ 
(1) 
Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2018 and 2017. For the year ended December 31, 2016, hedging gains were $308 million.
(2) 
Prior-period amounts are not adjusted under the modified-retrospective method of adoption of the new revenue recognition accounting standard.